Is there a survival benefit to prostate radiotherapy in patients with low‑volume metastatic hormone‑sensitive prostate cancer, and what radiation dose and fractionation schedule should be used?

Prostate Radiotherapy in Low-Volume Metastatic Hormone-Sensitive Prostate Cancer

Yes, prostate radiotherapy provides a survival benefit specifically in patients with low-volume metastatic hormone-sensitive prostate cancer, and should be delivered at 55 Gy in 20 fractions over 4 weeks or 36 Gy in 6 fractions over 6 weeks. 1

Survival Benefit Evidence

The survival benefit of prostate radiotherapy is restricted to patients with low metastatic burden (defined as fewer than 5 bone metastases and no visceral metastases). A meta-analysis of the HORRAD and STAMPEDE trials demonstrated approximately 7% improvement in 3-year overall survival in men with low-volume disease 1. The effect of prostate radiotherapy varied significantly by metastatic burden, with an interaction hazard ratio of 1.47 (95% CI 1.11-1.94, p=0.007), confirming that benefit is concentrated in the low-volume subset 1.

In unselected patients with metastatic disease, prostate radiotherapy does NOT improve overall survival (HR 0.92,95% CI 0.81-1.04, p=0.195) 2, 1. This is a critical distinction—the benefit disappears when treating all-comers with metastatic disease.

Defining Low-Volume Disease

Low-volume disease is defined as:

• Fewer than 5 bone metastases (M1b with ≤4 lesions) 1
• No visceral metastases (M1c excluded) 1, 3
• M1a (nodal-only) disease also benefits from prostate radiotherapy (HR 0.48,95% CI 0.39-0.58, p<0.001) 3
• PSA ≤10 ng/mL at diagnosis identifies a subset of M1b patients who benefit 4

Patients with M1c (visceral) metastases show no survival benefit from prostate radiotherapy (HR 0.91,95% CI 0.74-1.13) and should not receive it 3.

Recommended Dose and Fractionation

Two validated fractionation schedules were used in the STAMPEDE trial 2:

Option 1: Daily Schedule (Preferred)

• 55 Gy in 20 fractions over 4 weeks 2
• This represents moderate hypofractionation (2.75 Gy per fraction)

Option 2: Weekly Schedule

• 36 Gy in 6 fractions over 6 weeks 2
• This represents extreme hypofractionation (6 Gy per fraction)

Both schedules were well-tolerated with only 5% grade 3-4 acute toxicity during radiotherapy and 4% after completion 2. The choice between schedules can be based on patient convenience and institutional preference, as both were used in the trial that demonstrated benefit.

Alternative Emerging Approaches

For centers with appropriate technology:

• SBRT: 36.25 Gy in 5 fractions has been reported with excellent local control and minimal toxicity in low-volume metastatic patients 5
• MR-guided adaptive SBRT may optimize treatment delivery but remains investigational 5

Integration with Systemic Therapy

Prostate radiotherapy must be combined with systemic therapy—it is never used alone in metastatic disease 6. The specific systemic regimen matters:

With ADT Alone or ADT + Docetaxel

• Radiotherapy provides survival benefit in low-volume disease 1
• This was the context of the STAMPEDE and HORRAD trials 2, 1

With Intensified Systemic Therapy (ADT + Abiraterone)

• Recent data from PEACE-1 trial shows radiotherapy improves radiographic progression-free survival (HR 0.65,95% CI 0.45-0.93, p=0.02) in low-volume disease when combined with ADT and abiraterone 7
• However, no overall survival benefit has been demonstrated with this triplet combination 7
• The role of radiotherapy with modern androgen receptor pathway inhibitors (apalutamide, enzalutamide) remains undefined 8

Clinical Decision Algorithm

Offer prostate radiotherapy if ALL criteria met:

1. Newly diagnosed metastatic hormone-sensitive prostate cancer
2. Low metastatic burden: <5 bone metastases OR M1a nodal disease only
3. No visceral (M1c) metastases
4. Performance status adequate for radiotherapy
5. Life expectancy sufficient to realize survival benefit (typically >2 years)

Do NOT offer prostate radiotherapy if:

• High-volume disease (≥5 bone metastases or visceral metastases) 1, 3
• M1c visceral metastases present 3
• Patient receiving ADT + abiraterone + docetaxel (insufficient evidence of benefit) 7

Additional Benefits Beyond Survival

Even when overall survival is not improved, prostate radiotherapy provides:

• Reduction in local prostate-related events (urinary obstruction, bleeding, pain): 18% vs 30% in HORRAD, 12% vs 22% in PEACE-1 9
• Improved failure-free survival (HR 0.76,95% CI 0.69-0.84) 2
• Delayed time to castration resistance (HR 0.76,95% CI 0.70-0.82, p<0.001) 9
• Improved biochemical control (HR 0.74,95% CI 0.67-0.82) 2

These quality-of-life benefits may justify treatment even in scenarios where survival benefit is uncertain.

Common Pitfalls to Avoid

Do not extrapolate benefit to high-volume disease—multiple trials consistently show no benefit when metastatic burden is high 2, 1, 3. The interaction between treatment effect and disease volume is statistically significant and clinically meaningful.

Do not use suboptimal radiation doses—doses below 55 Gy equivalent are inadequate. A dose-response relationship exists, with higher biological effective doses associated with improved outcomes (HR 0.87 per 10 Gy increase, p=0.03) 10.

Do not delay systemic therapy to deliver radiotherapy—systemic therapy should be initiated promptly, with radiotherapy integrated into the treatment plan 6.